Guodian (Beijing) Pharmaceutical Technology

Guodian (Beijing) Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of induced pluripotent stem cell (iPSC) therapies for regenerative medicine. Founded in 2019 and headquartered in Beijing, the company focuses on creating standardized, clinical-grade cell products to treat neurological and degenerative diseases. Their core technology platform enables the efficient reprogramming of somatic cells and directed differentiation into specific therapeutic cell types, such as dopaminergic neurons and neural stem cells. Guodian's lead candidate, G-iPSC-001, is currently in clinical development for the treatment of Parkinson's disease. The company aims to provide scalable, "off-the-shelf" cell therapy solutions to address significant unmet medical needs in the global healthcare market.